Trial Profile
A Single-Center, Randomized, Double-Blind, Two-Way Crossover Study to Evaluate Whether a Single-Dose Administration of Crushed and Whole EMBEDA Induces Clinical Opiate Withdrawal Signs and Symptoms in Opioid-Dependent Patients With Chronic, Non-Cancer Pain Who Are Stabilized on EMBEDA.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2012
Price :
$35
*
At a glance
- Drugs Morphine/naltrexone (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Alpharma
- 22 Dec 2011 Results published in a Pfizer media release.
- 29 Nov 2011 Planned number of patients changed from 80 to 14 as reported by ClinicalTrials.gov.
- 04 Apr 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.